Congenital hematological disorder
MONDO:0009332A disorder of the blood that is present at birth.
Also known as: congenital haematological system disease, congenital hematological disorder, congenital hematological system disease
97 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a stem cell drug tame rare immune disease?
Disease control CompletedThis early-phase study tests whether Mozobil, a drug already used to boost stem cells for transplants, can safely raise white blood cell counts in people with WHIMS. WHIMS is a rare genetic condition that traps infection-fighting cells in the bone marrow, leading to frequent infe…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 05:00 UTC
-
Experimental drug aims to boost immunity in rare WHIM syndrome
Disease control CompletedThis phase 3 trial tests whether mavorixafor can raise neutrophil levels in people with WHIM syndrome, a rare genetic condition that weakens the immune system. Participants receive either mavorixafor or a placebo to see if the drug helps maintain infection-fighting white blood ce…
Phase: PHASE3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Rare disease drug shows promise in reducing infections
Disease control CompletedThis study tested two drugs, plerixafor and G-CSF, in 20 people with WHIM syndrome, a rare genetic condition that causes frequent infections and warts. Participants received each drug for a year and tracked their infections. The goal was to see which drug better reduced infection…
Phase: PHASE2, PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Promising new drug shows hope for rare anemia patients
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and help control the dis…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo shows promise for kids with rare immune disease
Disease control CompletedThis study tested a drug called alemtuzumab (Campath) as a first treatment for children with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening immune disorder. The goal was to see if it could help children survive until they could receive a stem cell transplan…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New transplant cocktail aims to cut complications in bone marrow failure
Disease control CompletedThis phase 2 trial tested a combination of treosulfan, fludarabine, and rabbit antithymocyte globulin before a bone marrow transplant in 40 people with bone marrow failure diseases like Diamond-Blackfan anemia and Shwachman-Diamond syndrome. The goal was to see if this conditioni…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for rare blood disorder: Long-Term drug study shows promise
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug mitapivat in 90 adults with pyruvate kinase deficiency, a rare genetic blood disorder that causes red blood cells to break down too quickly. Participants had already completed earlier studies of mitapivat and…
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene therapy offers hope for rare blood disorder
Disease control CompletedThis phase 1 trial tested a gene therapy called RP-L301 in 4 people with pyruvate kinase deficiency, a rare inherited blood disorder that causes severe anemia and often requires frequent blood transfusions. The treatment uses the patient's own blood stem cells, which are modified…
Phase: PHASE1 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:53 UTC
-
Could a natural compound help prevent cancer in a rare disease?
Prevention CompletedThis study tested whether quercetin, a natural substance found in some foods, could help prevent a type of mouth cancer in people with Fanconi anemia, a rare genetic condition that raises cancer risk. 48 participants took quercetin to see if it reduced certain cell changes linked…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Can a global patient registry unlock the secrets of a rare muscle disease?
Knowledge-focused CompletedThis study is building an international registry of people with GNE myopathy, an ultra-rare muscle disease that causes progressive weakness and often leads to wheelchair use. Participants will complete online questionnaires about their symptoms, medical history, quality of life, …
Sponsor: Newcastle University • Aim: Knowledge-focused
Last updated Aug 18, 2026 05:00 UTC
-
Scientists track rare muscle disease to unlock its secrets
Knowledge-focused CompletedThis study followed 78 people with GNE myopathy, a rare genetic disease that causes progressive muscle weakness starting in young adulthood. Researchers collected medical history, blood samples, and muscle function tests over up to two years to understand how the disease progress…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Blood cancer enzyme deficiency explored in new study
Knowledge-focused CompletedThis study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
C-Section bleeding study: does tranexamic acid help clotting?
Knowledge-focused CompletedThis study examined how the drug tranexamic acid (TXA) affects blood clotting in women having planned C-sections. Researchers measured clot breakdown times in 34 participants to see if TXA could help prevent heavy bleeding after delivery. The goal was to better understand how TXA…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Scientists hunt for hidden genes behind rare childhood disease
Knowledge-focused CompletedThis study looked for new genes that cause a rare condition called syndromic congenital neutropenia, where children are born with low infection-fighting white blood cells and other developmental issues. Researchers used advanced gene sequencing on 25 participants to find the gene…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Small step toward gene therapy for rare anemia
Knowledge-focused CompletedThis pilot study tested whether a combination of two drugs (G-CSF and plerixafor) could safely collect enough stem cells from the blood of children with Fanconi anemia for future gene therapy. Only 4 patients took part, and the main goal was to see if the cell collection process …
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:06 UTC